Ibrutinib 2, a Bruton’s tyrosine kinase (BTK) inhibitor approved for CLL [17], forms a covalent bond with cysteine residue Cys481 at the ATP binding site of BTK. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.